"For pharmaceutical executives, the lesson is clear: success in obesity will depend not only on science but also on vigilance, payer alignment, cultural reframing, and equitable access." But to understand this moment, it is important to trace the evolution of obesity drugs, why most failed, and what lessons the industry must carry forward
It means the scientific information needed to fully define its safety profile is incomplete
Depending on the patient, monitoring may include: Weight trends Waist circumference Blood pressure Glucose and A1C Lipids Liver markers Kidney markers Thyroid markers when appropriate Nutrient markers when indicated Hormone considerations when relevant Adjust the Plan as the Body Changes A patients needs at the start of treatment may not be the same after losing 20, 40, or 60 pounds
Symptoms of deficiency, including fatigue, numbness, cognitive fog, and mood changes, may return over weeks to months
The combination of sitagliptin and metformin is indicated in patients who are not adequately controlled on metformin or sitagliptin alone or in patients already taking both agents
Polyethylene glycol (PEG) is one of the rare synthetic polymers approved by the FDA for in vivo injection, which has low relative molecular weight polydispersity, good aqueous phase and organic solubility, and is widely used in the modification of protein drugs
